Corporate Profile
Cognition Therapeutics is a clinical-stage biopharmaceutical company leveraging our expertise in the σ-2 (sigma-2) receptor to develop innovative, small molecule therapeutics targeting age-related degenerative diseases. Our initial focus is on degenerative diseases of the CNS and retina such as Alzheimer’s disease, dementia with Lewy bodies and dry age-related macular degeneration.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
May 23, 2023
May 18, 2023
May 04, 2023
Events
Jun 12 - Jun 14, 2023
Apr 13, 2023
Mar 28 - Apr 1, 2023
Latest SEC Filings
Form | Filing date | Description |
---|---|---|
SC 13G | A statement of beneficial ownership of common stock by certain persons |
|
DEFA14A | Additional proxy soliciting materials - definitive |
|
DEFA14A | Additional proxy soliciting materials - definitive |